We found significant differences in the immune parameters, specifically CD3+ and CD8+ T-cells in HPC products between MM patients who did and those who did not develop autoGVHD (P = 0.047 and 0.038, resp). The gene discussed is CD8A; the disease is Miyoshi myopathy.